INSMED INC Selling, General and Administrative Expense
INSMED INC (INSM) reported Selling, General and Administrative Expense of $247.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- INSMED INC selling, general and administrative expense for the quarter ending 2026-06-30 was $247.47M, a 59.90% increase year-over-year.
- INSMED INC selling, general and administrative expense for the quarter ending 2026-03-31 was $247.26M, a 67.58% increase year-over-year.
- INSMED INC selling, general and administrative expense for the quarter ending 2025-12-31 was $212.48M, a 49.10% increase year-over-year.
- INSMED INC selling, general and administrative expense for the quarter ending 2025-09-30 was $186.38M, a 56.71% increase year-over-year.
- INSMED INC selling, general and administrative expense for fiscal 2025 was $701.17M, a 52.06% increase from fiscal 2024.
- INSMED INC selling, general and administrative expense for fiscal 2024 was $461.12M, a 33.85% increase from fiscal 2023.
- INSMED INC selling, general and administrative expense for fiscal 2023 was $344.50M, a 29.62% increase from fiscal 2022.
- INSMED INC selling, general and administrative expense for fiscal 2022 was $265.78M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $247.47M 10-Q · filed 2026-08-06 | $494.73M 10-Q · filed 2026-08-06 | $707.21M derived: sum of 3 quarters · filed 2026-08-06 | $893.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $247.26M 10-Q · filed 2026-05-07 | $459.74M derived: sum of 2 quarters · filed 2026-05-07 | $646.12M derived: sum of 3 quarters · filed 2026-05-07 | $800.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $212.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $398.86M derived: sum of 2 quarters · filed 2026-02-19 | $553.62M derived: sum of 3 quarters · filed 2026-08-06 | $701.17M 10-K · filed 2026-02-19 |
| 2025-09-30 | $186.38M 10-Q · filed 2025-10-30 | $341.14M derived: sum of 2 quarters · filed 2026-08-06 | $488.68M 10-Q · filed 2025-10-30 | $631.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $154.76M 10-Q · filed 2026-08-06 | $302.31M 10-Q · filed 2026-08-06 | $444.82M derived: sum of 3 quarters · filed 2026-08-06 | $563.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $147.54M 10-Q · filed 2026-05-07 | $290.06M derived: sum of 2 quarters · filed 2026-05-07 | $408.99M derived: sum of 3 quarters · filed 2026-05-07 | $515.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $142.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $261.44M derived: sum of 2 quarters · filed 2026-02-19 | $368.01M derived: sum of 3 quarters · filed 2026-02-19 | $461.12M 10-K · filed 2026-02-19 |
| 2024-09-30 | $118.93M 10-Q · filed 2025-10-30 | $225.50M derived: sum of 2 quarters · filed 2025-10-30 | $318.60M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $106.57M 10-Q · filed 2025-08-07 | $199.67M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $93.10M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $344.50M 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $265.78M 10-K · filed 2025-02-20 | |||
| 2011-09-30 | $2.47M 10-Q · filed 2011-11-09 | $5.22M derived: sum of 2 quarters · filed 2011-11-09 | $8.47M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $2.75M 10-Q/A · filed 2011-08-08 | $6.00M 10-Q/A · filed 2011-08-08 | ||
| 2010-09-30 | $1.64M 10-Q · filed 2011-11-09 | $3.52M derived: sum of 2 quarters · filed 2011-11-09 | $5.06M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $1.88M 10-Q/A · filed 2011-08-08 | $3.42M 10-Q/A · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |